Testosterone Replacement Therapy for Male Hypogonadism: Part III. Pharmacologic and Clinical Profiles, Monitoring, Safety Issues, and Potential Future Agents

Total Page:16

File Type:pdf, Size:1020Kb

Testosterone Replacement Therapy for Male Hypogonadism: Part III. Pharmacologic and Clinical Profiles, Monitoring, Safety Issues, and Potential Future Agents International Journal of Impotence Research (2007) 19, 2–24 & 2007 Nature Publishing Group All rights reserved 0955-9930/07 $30.00 www.nature.com/ijir REVIEW Testosterone replacement therapy for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents A Seftel Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, USA Male hypogonadism is associated with potentially distressing adverse effects on diverse organs and tissues. These include sexual dysfunction, particularly diminished libido, as well as mood disturbances, reduced lean body mass, and increased adipose-tissue mass. A wide range of effective and well-tolerated options exists. These include relatively noninvasive therapies, such as testosterone (T) gels and T patches; slightly more invasive treatments, such as the T buccal system; and invasive therapies, such as intramuscular T injections and subcutaneous depot implants (T pellets). Testosterone replacement therapy (TRT) can be individualized to enhance patient health and well-being. Screening and ongoing monitoring are necessary to ensure both the efficacy and safety of TRT, particularly prostate safety. Investigational agents, including selective androgen receptor modulators, may offer new pharmacodynamic and/or pharmacokinetic properties that enhance outcomes of TRT. International Journal of Impotence Research (2007) 19, 2–24. doi:10.1038/sj.ijir.3901366; published online 29 September 2005 Keywords: efficacy; hypogonadism; pharmacokinetics; safety; testosterone; tolerability Introduction improvements in sexual desire and quality of life, in hypogonadal men receiving adjunctive TRT, includ- Testosterone replacement therapy (TRT) has been ing sildenafil nonresponders.3,4 administered to men with hypogonadism for dec- Contraindications to the use of exogenous testos- ades.1 The fundamental aim of TRT is to restore terone formulations, which are Schedule III con- serum T to eugonadal levels and minimize signs and trolled substances, include prostate cancer (PCa), symptoms of hypogonadism. Sexual dysfunction, breast cancer, and/or untreated prolactinoma.5 TRT particularly low libido, is among the most readily with any of the modalities described herein should reversible symptoms of male hypogonadism. The be instituted according to the screening and mon- most recent erectile dysfunction (ED) consensus itoring guidelines, which are detailed in this review. guidelines recommend evaluation of the hypotha- lamic–pituitary–gonadal axis, including total T, Topical/transdermal therapies bioavailable T (BT), and free T (FT), ‘in patients with sexual dysfunction and at risk of or suspected Testosterone topical gels (T Gels) of hypogonadism.’2 These guidelines designate Pharmacologic profiles. Two 1% hydroalcoholic testosterone as a second-line therapy. Recent studies T gels have been approved by the US Food and Drug have demonstrated significant short-term improve- Administration (FDA) for male hypogonadism: ments in erectile function, as well as longer-term s AndroGel from UniMed Pharmaceuticals (Deer- field, IL, USA) and Solvay Pharmaceuticals (Mar- ietta, GA, USA), and Testims from Auxilium Pharmaceuticals (Malvern, PA, USA).6,7 Each 5- to Correspondence: Dr A Seftel, Department of Urology, Case Western Reserve University, 11100 Euclid Avenue, 10-g tube or packet of 1% gel contains 50–100 mg of Cleveland, OH 44106-5046, USA. T. Each gel is formulated with a skin-penetration E-mail: [email protected] enhancer and is X67.0% ethanol by volume. After Received 2 March 2005; accepted 7 June 2005; published daily (preferably morning) application of each agent online 29 September 2005 to clean, dry, intact skin of the upper arms or Testosterone replacement therapy A Seftel 3 shoulders (and/or abdomen), 10% of each dose desire and erectile function following daily treat- (5–10 mg) is absorbed into the systemic circulation ment with topical T gel 5 g of a 1% testosterone over a 24-h period. hydroalcoholic gel daily (AndroGels; Besins Inter- national, Paris, France). Following 3 months of such treatment, the mean serum T was restored to Clinical studies 1013 ng/dl and normalized in all patients. In 31 Pharmacokinetics. T gels provide longer-lasting (63%) of the 49 men, scores on both the sexual elevations of serum T compared with a transdermal desire and erectile function domains of the IIEF patch (T patch).8 In a study involving equivalent were significantly improved compared with base- doses of two T gels,9 Testim treatment was asso- line, with the sexual desire domain more than ciated with significantly higher serum T levels and doubling (from 4 to 8.9; P 0.001) and the erectile bioavailability than Androgel; the two formulations o function domain nearly doubling (from 15.0 to 26; were not biologically equivalent: both the C and max P 0.001); the final value of 26 has been associated AUC0-24 for T delivered by Testim were 30% higher o with no ED in prior studies.18 than the values for T delivered by Androgel (Table 1). A total of 17 patients did not have significant T delivered by gel formulations undergoes no first- improvements in sexual function following 3 months pass hepatic metabolism. of T-gel therapy as determined by negative responses to the Global Assessment Question (GAQ), ‘Has Efficacy. Several multicenter, randomized con- treatment improved your erections?’ However, these trolled trials have demonstrated that restoration patients did experience some improvements, with of serum T levels with T gel was associated with normalization of serum T and BT and an increase in improvements in sexual function,3,10–12 as well as the erectile function domain of the IIEF (from 13.6 to body composition, mood, and/or bone markers11–13 22 following T-gel monotherapy). Following treatment (Table 1). In one study, threshold serum T values with an adjunctive sildenafil (100 mg)-T-gel regimen (Cavg) were identified above which significant im- for a further 3 months, the mean erectile function provements were noted: 500 ng/dl for the frequency score increased to 27, which is consistent with no of sexual intercourse and 600 ng/dl for self-rated ED, and all patients answered the GAQ positively. sexual desire (Figure 1).10 The frequency of night Two patients discontinued treatment because of time erections rose significantly even when serum T urination difficulties. Nine patients reported irritation levels were low-normal (Cavg ¼ 400 ng/dl), suggest- at the T-gel application site, but no patient dis- ing that this androgenic effect may be among the continued therapy.18 earliest to be observed during TRT. Finally, a US group recently reported that treat- The benefits of adjunctive or ‘rescue’ TRT with a T ment of 18 hypogonadal men with depression using gel were shown in studies of hypogonadal men with T gel (5 g of a 1% gel; AndroGels; Unimed refractory depression14 or with moderate-severe ED Pharmaceuticals) for up to 12 weeks significantly nonresponsive to sildenafil3 (Table 1). The results improved scores on the Hamilton Rating Scale for from the study of men with ED were particularly Depression compared with baseline but not com- noteworthy because 16% of patients also had pared with a placebo phase of equal duration.19 diabetes mellitus, which frequently renders ED There were no clinically significant changes in more severe, refractory to treatment, and a greater hemoglobin, hematocrit, or prostate-specific antigen burden on quality of life.15,16 (PSA) between the T-gel and placebo phases.19 Three important studies concerning T and both sexual function and depression have been published in 2005. Studying 162 elderly (mean age ¼ 64.1 Tolerability and safety. T gels have been well years) men with ED (mean duration ¼ 45.6 months), tolerated in trials of up to 6 months. According to a Korean group reported that hypogonadism (serum the US product labeling for Testim, adverse events To300 ng/dl) was among the strongest independent (AEs) judged to be possibly, probably, or definitely predictors of a poor response to sildenafil 25–100 mg related to T gel in 0–2% of patients included for 8 weeks. Only poor pretreatment erectile func- headache, hot flushes, insomnia, increased blood tion (International Index of Erectile Function (IIEF) pressure or increased hematocrit or hemoglobin.7 erectile function domain score o17) was a stronger AEs considered to be possibly, probably, or defi- independent prognostic factor (OR ¼ 2.2; 95% nitely related to AndroGel included acne (1–8% of CI ¼ 1.45–7.33).17 patients); headache (up to 4%); as well as emotional Consistent with this report, an Israeli group lability, nervousness, gynecomastia, or mastodynia demonstrated that short-term treatment with (up to 3%).6 Application-site reactions represent the either T gel or adjunctive T gel with sildenafil most frequent complaints with both T gels, occur- has potential clinical benefits in hypogonadal ring in up to 5% of patients.6,7 men (mean age ¼ 60.7 years) with ED.18 In this study With regard to prostate safety, 2.8–18.8% of 106 of 49 hypogonadal men (mean serum T ¼ 378 ng/dl), men receiving T gel (AndroGel) 50–100 mg experi- 31 reported significant improvements in both sexual enced prostate enlargement or elevation in PSA International Journal of Impotence Research International Journal of Impotence Research 4 Table 1 T Gels: pharmacokinetics, efficacy, and safety Study Treatment Design Pharmacokinetics Efficacy Safety/tolerability Pharmacokinetics7efficacy
Recommended publications
  • NAMS Practice Pearl
    NAMS Practice Pearl Extended Duration Use of Menopausal Hormone Therapy Released October 1, 2013 Andrew M. Kaunitz, MD, NCMP (University of Florida College of Medicine-Jacksonville, Department of Obstetrics & Gynecology, Jacksonville, FL) Although providing guidance to patients regarding duration of hormone therapy represents a topic surrounded by controversy, clinicians often encounter this issue in practice. As pointed out in the NAMS 2012 Hormone Therapy (HT) Position Statement, determining the optimal duration of HT is challenging both for clinicians and for patients. This Practice Pearl addresses clinical situations for which long-term HT might be appropriate and provides practical guidance regarding prudent therapeutic choices for women using HT for an extended duration. Use of Systemic HT to Treat Vasomotor Symptoms (VMS). Moderate to severe VMS represent the most common indication for systemic combination estrogen-progestin (EPT) or estrogen-only (ET) HT, and HT represents the most effective treatment for VMS.1 Some experts’ recommendations regarding HT duration of use have cautioned that “…it remains prudent to keep the… duration of treatment short” or that HT “…may serve a useful role in short-term symptom management.”2,3 However, VMS persist for longer than many have assumed. For instance, The Penn Ovarian Aging Study was conducted specifically to estimate the duration of moderate-to-severe VMS and found that median duration of such symptoms was 10.2 years. In this landmark cohort study, the median duration of VMS that started
    [Show full text]
  • Transdermal Versus Oral Estrogen: Clinical Outcomes in Patients
    Journal of Assisted Reproduction and Genetics https://doi.org/10.1007/s10815-018-1380-5 ASSISTED REPRODUCTION TECHNOLOGIES Transdermal versus oral estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial Semra Kahraman1 & Caroline Pirkevi Çetinkaya1 & Yucel Sahin1 & Gokalp Oner1 Received: 20 September 2018 /Accepted: 26 November 2018 # The Author(s) 2018 Abstract Purpose To conduct a non-inferiority study to compare the clinical outcomes of transdermal estrogen patch and oral estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. Methods A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Results Endometrial thickness and clinical outcomes of oral and transdermal estrogen administration were equally successful (p >0.05). Conclusion No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal estrogen and oral estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression. Keywords Oral estrogen .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,503,894 B1 Dudley Et Al
    USOO6503894B1 (12) United States Patent (10) Patent No.: US 6,503,894 B1 Dudley et al. (45) Date of Patent: Jan. 7, 2003 (54) PHARMACEUTICAL COMPOSITION AND 5,460.820 A 10/1995 Ebert et al. METHOD FOR TREATING 5,610,150 A 3/1997 Labrie HYPOGONADISM 5,629,021. A 5/1997 Wright 5,641,504. A 6/1997 Lee et al. (75) Inventors: Robert E. Dudley, Kenilworth, IL 5,643,899 A 7/1997 Elias et al. (US); S. George Kottayil, Long Grove, (List continued on next page.) IL (US); Olivier Palatchi, L'Hayles FOREIGN PATENT DOCUMENTS Roses (FR) DE 3238984 10/1982 (73) Assignees: Unimed Pharmaceuticals, Inc., EP O581.587 A2 2/1994 Marietta, GA (US); Laboratories EP O197753 10/1996 Besins Iscovesco, Herndon, VA (US) EP O804926 4/1997 FR 2515041 4/1983 (*) Notice: Subject to any disclaimer, the term of this FR 2518879 7/1983 patent is extended or adjusted under 35 FR 2519252 7/1983 U.S.C. 154(b) by 0 days. FR 2.705572 12/1994 GB 2109231 6/1983 (21) Appl. No.: 09/651,777 WO WO 93/25168 A1 12/1993 WO 9408590 4/1994 (22) Filed: Aug. 30, 2000 WO 9421230 9/1994 WO 9421271 9/1994 (51) Int. Cl................................................. A61K 31/56 WO WO-96/27372 A1 * 9/1996 .......... A61 K/31/21 (52) U.S. Cl. ........................................ 514/178; 514/177 WO 9636339 11/1996 (58) Field of Search ................................. 514/178, 396, WO 9743989 11/1997 514/406, 415, 177 WO 98O8547 3/1998 WO 9824451 6/1998 (56) References Cited WO WO 98/34621 A1 8/1998 U.S.
    [Show full text]
  • The History of Estrogen Therapy
    REVIEW The History of Estrogen Therapy Grace E. Kohn,1 Katherine M. Rodriguez, MD,2 James Hotaling, MD,3 and Alexander W. Pastuszak, MD, PhD3 ABSTRACT Introduction: Menopausal hormone therapy (MHT) has proven an effective treatment for the amelioration of symptoms of menopause. The idea that a substance was the missing factor in a woman’s body after menopause dates to the 1800s, when cow ovarian tissue was injected into German women in a successful attempt to reverse the sexual symptoms of menopause. The early 1900s saw the rise of commercialized menopause “treatments” that ranged in substance and even theoretical efficacy. The role of estrogen was first accurately described in Guinea pigs in 1917 by Dr. Papanicolaou. Aim: To tell the detailed history of how estrogen was discovered and the controversy surrounding MHT. Methods: A literature search was conducted using PubMed to identify relevant studies and historical documents regarding the history of estrogen therapy. Results: The history of estrogen supplementation and its controversies are interesting stories and relevant to today’s ongoing investigation into hormone replacement. Conclusion: The controversy of MHT remained until the first randomized trials examining MHT in the early 1990s that suggested MHT is cardioprotective in postmenopausal women, although this conclusion was contradicted in subsequent trials. In the present day, MHT is approved only for short-term use for the symptomatic treatment of menopause. Kohn GE, Rodriguez KM, Hotaling J, et al. The History of Estrogen Therapy. Sex Med Rev 2019;XX:XXXeXXX. Copyright Ó 2019, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
    [Show full text]
  • An Update the Increasing Popularity of Anabolic Androgenic Steroids
    Anabolic Androgenic Steroid Abuse in the United Kingdom; An Update The increasing popularity of anabolic androgenic steroids. Carrie Mullena, Benjamin J Whalleyb, Fabrizio Schifanoc, Julien S Bakerd a School of Computing, Engineering and Physical Sciences, University of the West of Scotland, Paisley, PA1 2BE b School of Chemistry, Food and Nutritional Sciences, and Pharmacy, The University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP c School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, AL10 9EU d Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong. Correspondence Carrie Mullen, School of Computing, Engineering and Physical Sciences, University of the West of Scotland, Paisley, PA1 2BE Tel 0044 141 848 3845 email [email protected] 7,081 Words Abstract Anabolic androgenic steroids (AASs) are prescribed for medical conditions related to low testosterone. Abuse of AASs has surged as they become increasingly recognised as potent image enhancement drugs. The primary goal of most abusers is to obtain what they consider to be a more attractive outward appearance. Abuse is complex. There are a vast range of AAS substances available, although due to their illicit nature, the true composition of AAS substances is difficult to evaluate. Users follow dosing patterns which incorporate a number This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.14995 This article is protected by copyright.
    [Show full text]
  • Estradiol Transdermal System)
    Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle® (Estradiol Transdermal System) Minivelle now approved for prevention of postmenopausal osteoporosis at all doses New 0.025 mg/day Minivelle, for osteoporosis only, is the smallest estrogen patch ever Miami, FL and New York, NY, September 24, 2014 -- Noven Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. With this new approval, women who are using Minivelle to treat their VMS symptoms have the benefit of also helping to prevent osteoporosis. The new 0.025 mg/day patch is 33% smaller than Minivelle 0.0375 mg/day that is already only about the size of a dime, the planet’s smallest estrogen therapy patch ever. Minivelle is now approved with five dosing options – 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day, with the newly approved, lower dose of 0.025 mg/day indicated for the prevention of postmenopausal osteoporosis only. If a patient uses Minivelle only to prevent osteoporosis from menopause, they should talk with their healthcare provider about whether a different treatment or medicine without estrogens might be better for them. “Noven is deeply committed to offering therapies that address women’s menopausal health,” said Joel Lippman, M.D., FACOG, Noven’s Executive Vice President – Product Development and Chief Medical Officer.
    [Show full text]
  • New Long-Acting Androgens
    World J Urol (2003) 21: 306–310 DOI 10.1007/s00345-003-0364-x TOPIC PAPER Louis J. Gooren New long-acting androgens Received: 16 September 2003 / Accepted: 17 September 2003 / Published online: 9 October 2003 Ó Springer-Verlag 2003 Abstract Testosterone substitution treatment aims to are usually irreversible. The consequence is that life-long replace physiological actions of endogenous testosterone androgen replacement is required. Patient compliance by steadily maintaining physiological blood levels of with life-long androgen replacement depends on conve- testosterone. The underlying conditions rendering nient pharmaceutical formulations ensuring continuity androgen replacement necessary are usually irreversible. of androgen replacement. The benefits of androgen The consequence is that almost life-long androgen replacement therapy are clear, but the delivery of tes- replacement is required. Patient compliance with life- tosterone to hypogonadal men in a way that approxi- long androgen replacement depends on convenient mates normal levels and patterns still poses a therapeutic pharmaceutical formulations ensuring continuity of challenge. Among experts, there is consensus that the androgen replacement. Therefore, they must be conve- major goal of testosterone substitution is ‘‘to replace nient in usage with a relative independence of medical testosterone levels at as close to physiological concen- services. In elderly man, safety of androgen replacement trations as is possible’’ [18]. General agreements about therapy is a concern but in younger subjects (below the such an androgen replacement therapy are (1) a delivery age of 50 years) side effects of androgens are usually of the physiological amount of testosterone (3-10 mg/d); minimal. For them, long-acting testosterone prepara- (2) consistent levels of testosterone, 5a-dihydrotestos- tions are well suited.
    [Show full text]
  • Contraceptive Technology Update
    The Trusted Source for Contraceptive and STI News and Research for More Than Three Decades March 2014: Vol. 35, No. 3 Pages 25-36 Options might begin to emerge IN THIS ISSUE with new data out on LARC n LARC methods: Data Time to embrace evidence-based practice as choice options may expand emerges as choices might expand �������������������������������������cover rogress is being made on the long-acting reversible contraception n Interpregnancy intervals: (LARC) front to promote top-tier effective methods to women. What can be done to aid P According to the New York City-based Guttmacher Institute, spacing? ����������������������������������������28 in 2009, 8.5% of women using contraceptives relied on such LARC n Dysmenorrhea: Science methods as the implant (Nexplanon, Merck & Co., Whitehouse Station, eyes “little blue pill” for NJ) and the intrauterine device (IUD), reflecting a rise from 5.5% 1 treatment . 29 in 2007 and 2.4% in 2002. Currently U.S.-approved IUDs include ParaGard, Teva Women’s Health, North Wales, PA, and Mirena, Bayer n Transdermal contraception: HealthCare Pharmaceuticals, Wayne, NJ. Most of the women who use Will women see more long-acting reversible methods choose IUDs; nearly 8% of women using choices? . 31 contraception use the IUD, and less than 1% use the implant.1 n Adolescent patients: Not all With a 2012 American College of Obstetricians and Gynecologists providers discuss sex ����������������32 committee opinion stating that long-acting reversible contraceptives such as the IUD and the contraceptive implant are safe, effective, and n Washington Watch: U.S. 2 Supreme Court to review appropriate options for adolescents.
    [Show full text]
  • Estradot® Estradiol
    Estradot® estradiol Consumer Medicine Information What is in this leaflet A study called the Women's Health HRT should not be used for the long- Initiative indicated increased risk of term maintenance of general health This leaflet answers some common heart attack, stroke, breast cancer, or to prevent heart disease or questions about the menopause and blood clots in the legs or lungs in dementia. ("change of life"), hormone women receiving treatment with a Estradot is not suitable for birth replacement therapy and Estradot. product containing conjugated control and it will not restore estrogens 0.625 mg and the It does not contain all the available fertility. progestogen medroxyprogesterone information. It does not take the acetate (MPA). The researchers place of talking to your doctor or How it works stopped the study after 5 years when pharmacist. it was determined the risks were Estradiol is a natural female sex The information in this leaflet was greater than the benefits in this hormone called an estrogen. It is the last updated on the date listed on the group. The Women's Health same hormone that your ovaries were final page. More recent information Initiative Memory Study indicated producing before the menopause. on the medicine may be available. increased risk of dementia in women The menopause occurs naturally in You should ensure that you speak aged 65-79 years taking conjugated the course of a woman's life, usually to your pharmacist or doctor to estrogens and MPA. There are no between the ages of 45 and 55. It obtain the most up-to-date comparable data currently available may happen sooner if the ovaries are information on the medicine.
    [Show full text]
  • Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands
    Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Amanda Jones, M.S. Graduate Program in Pharmacy The Ohio State University 2010 Dissertation Committee: James T. Dalton, Advisor Thomas D. Schmittgen William L. Hayton Robert W. Brueggemeier Copyright by Amanda Jones 2010 Abstract The androgen receptor (AR) is critical for the growth and development of secondary sexual organs, muscle, bone and other tissues, making it an excellent therapeutic target. Ubiquitous expression of AR impedes the ability of endogenous steroids to function tissue selectively. In addition to the lack of tissue selectivity, clinical use of testosterone is limited due to poor bioavailability and pharmacokinetic problems. Our lab, in the last decade, discovered and developed tissue selective AR modulators (SARMs) that spare androgenic effects in secondary sexual organs, but demonstrate potential to treat muscle wasting diseases. This work reveals the discovery of next generation SARMs to treat prostate cancer and mechanistically characterize a prospective SARM in muscle and central nervous system (CNS). Prostate cancer relies on the AR for its growth, making it the primary therapeutic target in this disease. However, prolonged inhibition, with commercially available AR antagonists, leads to the development of mutations in its ligand binding domain resulting in resistance. Utilizing the crystal structure of AR-wild-type and AR-W741L mutant, we synthesized a series of AR pan- antagonists (that inhibit both wild-type and mutant ARs). Structure activity relationship studies indicate that sulfonyl and amine linkages of the aryl propionamide pharmacophore are important for the antagonist activity.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0078091 A1 Hubler Et Al
    US 20070078091A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0078091 A1 Hubler et al. (43) Pub. Date: Apr. 5, 2007 (54) PHARMACEUTICAL COMBINATIONS FOR (30) Foreign Application Priority Data COMPENSATING FORATESTOSTERONE DEFICIENCY IN MEN WHILE Sep. 6, 1998 (DE)..................................... 198 2.55918 SMULTANEOUSLY PROTECTING THE PROSTATE Publication Classification (76) Inventors: Doris Hubler, Schmieden (DE): (51) Int. Cl. Michael Oettel, Jena (DE); Lothar A6II 38/09 (2007.01) Sobek, Jena (DE); Walter Elger, Berlin A 6LX 3/57 (2007.01) (DE); Abdul-Abbas Al-Mudhaffar, A6II 3/56 (2006.01) Jena (DE) A 6LX 3/59 (2007.01) A 6LX 3/57 (2007.01) A61K 31/4709 (2007.01) Correspondence Address: A6II 3L/38 (2007.01) MILLEN, WHITE, ZELANO & BRANGAN, (52) U.S. Cl. ............................ 514/15: 514/171; 514/170; P.C. 514/651; 514/252.16; 514/252.17; 22OO CLARENDON BLVD. 514/3O8 SUTE 14OO ARLINGTON, VA 22201 (US) (57) ABSTRACT This invention relates to pharmaceutical combinations for (21) Appl. No.: 11/517,301 compensating for an absolute and relative testosterone defi ciency in men with simultaneous prophylaxis for the devel opment of a benign prostatic hyperplasia (BPH) or prostate (22) Filed: Sep. 8, 2006 cancer. The combinations according to the invention contain a natural or synthetic androgen in combination with a Related U.S. Application Data gestagen, an antigestagen, an antiestrogen, a GnRH analog. a testosterone-5C.-reductase inhibitor, an O-andreno-receptor (63) Continuation of application No. 09/719,221, filed on blocker or a phosphodiesterase inhibitor. In comparison to Feb. 16, 2001, filed as 371 of international application the combinations according to the invention, any active No.
    [Show full text]
  • Hormone Replacement Therapy and Effects on Mood
    Umeå University Medical Dissertations New series No. 830 ISSN 0346-6612 ISBN 91-7305-404-6 From the Department of Clinical Sciences, Obstetrics and Gynecology, ; Umeå University, Umeå, Sweden Hormone replacement therapy and effects on mood Inger Björn Umeå 2003 Umeå University Medical Dissertations New series No. 830 • ISSN 0346-6612 • ISBN 91-7305-404-6 From the Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden Hormone replacement therapy and effects on mood AKADEMISK AVHANDLING som med vederbörligt tillstånd av Rektorsämbetet vid Umeå Universitet för avläggande av medicine doktorsexamen offentligen kommer att försvaras i Betula, Lecturer Hall, byggnad 6M, bottenvåningen, Norrlands Universitets sjukhus, fredagen den 16 maj, 2003, kl 10.00 av Inger Björn * 1 - V* A.V Umeå 2003 Fakultetsopponent: Professor Bo von Schoultz Institutionen för Kvinnor och Barns hälsa, Karolinska sjukhuset, Stockholm ABSTRACT Hormone replacement therapy and effects on mood Inger Björn Background: During the past 5 decades, hormone replacement therapy (HRT) has been used, and appreciated for its beneficial effects, by millions of women in their menopause. As treatment for climacteric symptoms, estrogen is outstanding, and effects on hot flushes, vaginal dryness, and insomnia have been widely documented. The increased risks of venous thrombosis and breast cancer, however, restrict the use of estrogen. Estrogen treatment in women with a remaining uterus includes a progestin, added to protect the endometrium from hyperplasia and malignancies. The long-standing clinical impression, that progestin addition negatively influences mood, has been discussed in previous studies. Mood deterioration is, however, not mortal, although mood is important to the wellbeing and daily functioning of women treated with hormones.
    [Show full text]